While some of the misconceptions of palliative care have been cleared up over the years, it is still very much associated with end-of-life care, explained Judith Peres, LCSW-C, clinical social worker and health policy consultant.
While some of the misconceptions of palliative care have been cleared up over the years, it is still very much associated with end-of-life care, explained Judith Peres, LCSW-C, clinical social worker and health policy consultant.
Transcript (slightly modified)
What are some of the misconceptions that still exist about palliative care and end-of-life care?
One of the things that has been important in recent years, over the last couple of decades, is the decoupling of palliative care from hospice. Hospice is the deliverer and provider of palliative care, but palliative care can also be delivered outside of hospice, alongside of concurrent care with acute care issues and really is that extra layer of care that would help people with their symptoms and their concerns.
What cultural challenges do you run into in palliative care discussions, and how can and are providers handling them?
I think people are very much still associating palliative care with end-of-life care without looking at it as being something that is that extra layer of support that they can use and need throughout the advance of a serious illness. And I think one of the things that is important is for people to recognize that it is something that can help them along the way.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More